leadf
logo-loader
viewBioPorto

BioPorto Diagnostics A/S looks for FDA approval for its kidney diagnostic test

BioPorto Diagnostics A/S (CPH:BIOPOR) CEO Peter Eriksen joins Proactive Investors at the 11th Annual Biotech Showcase in San Francisco.

The Copenhagen, Denmark based in-vitro diagnostics company provides healthcare professionals in clinical and research settings a range of diagnostic tests and antibodies. Its product portfolio includes assays for underserved disease states such as NGAL for acute kidney injury.

Quick facts: BioPorto

Price: 0.4 USD

PINK:THOXF
Market: PINK
Market Cap: $106.63 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of BioPorto named herein, including the promotion by the Company of BioPorto in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

BioPorto Diagnostics reveals progress on its co-developed 10-minute...

BioPorto Diagnostics A/S (CPH:BIOPOR) CEO Peter Eriksen tells Proactive its fast-track collaboration with the University of Southern Denmark (SDU) to create a 10-minute test for the coronavirus (COVID-19) has yielded promising results in tests against heat-inactivated virus. Eriksen says in the...

on 09/18/2020

2 min read